Skip to main content

Research & Innovation

Fox Group

Dr Fox collaborates internationally within the fields of HIV and SARS-CoV-2 infection.

Members

Julie Fox

Lead Investigator

Sophie Lam

Project Manager

HIV virus

CHAPS

The Combined HIV Adolescent Prevention Study (CHAPS) is a collaborative African / European HIV prevention study running in South Africa, Uganda and Zimbabwe from 2018 to 2021. The overall aims of the project are to investigate the acceptability and feasibility of implementing daily and on-demand PrEP (pre-exposure prophylaxis) among adolescents in South Africa, Uganda and Zimbabwe and to determine an on-demand PrEP dosing schedule for insertive sex. The study is divided into 3 separate phases; phase 1 is a Social Science study with the aim of identifying barriers to medication adherence, phase 2 is the clinical trial which involves giving men TDF-FTC or TAF-FTC as oral PrEP before Voluntary Male Medical Circumcision and evaluating protection through ex vivo challenge while phase 3 will investigate the efficacy of postexposure administration of the drugs.

CHAPS (Combined HIV Adolescent Prevention Study)

covid virus

COVAB: COVID-19 antibody repertoires in infection and vaccination

COVAB is a collaboration between the UK, South African, Sweden and Uganda to explore SARS-CoV-2 infection in terms of antibody development, mechanisms of transmission and ways to engage the public in vaccine delivery. The programme builds on capacity development from the EDCTP-CHAPS HIV prevention programme led by Dr Fox.

COVAB-B

COVAB- B is a collaboration between the UK and Switzerland to explore SARS-CoV-2 antibody repertoires in infection and following vaccination . The programme builds on capacity development from the EDCTP- SARS-CoV-2- COVAB programme led by Dr Fox.

HIV test

PrEPVacc

PrEPVacc is a combination HIV vaccine + pre-exposure prophylaxis (PrEP) phase IIb study using an innovative adaptive trial design. PrEPVacc is exploiting >20 years of European HIV research to demonstrate the efficacy of two regimens of experimental DNA, MVA and Env protein/adjuvant vaccines. All these PrEPVacc GMP vaccine products have already been studied in Europe and Africa in >600 volunteers, and are safe and immunogenic.

CHERUB

CHERUB is one of the first cooperatives of UK Biomedical Research Centres to explore one of the most exciting new fields of biomedical research – HIV Cure. Internationally-recognised researchers from five Biomedical Research Centers are working together to provide a unique experimental medicine approach to new HIV therapeutic strategies. CHERUB will be the UK’s flagship in this field, bringing together, amongst others, clinicians, virologists, immunologists, molecular biologists and mathematical modellers under the umbrella of the National Institute of Health Research.

Self-start HIV Post exposure prophylaxis (PEPSE), to reduce time to first dose and increase efficacy
Fox, J., Lee, M. J., Fairhead, C., Ledwaba-Chapman, L., Nori, A., McQuillan, O., Wang, Y., Clarke, A. & Menon-Johansson, A., 4 Dec 2022, (Accepted/In press) In: SEXUALLY TRANSMITTED INFECTIONS. Research output: Contribution to journal › Article › peer-review
Symptoms of post-traumatic stress and associations with sexual behaviour and PrEP preferences among young people in South Africa, Uganda and Zimbabwe
for the CHAPS Study Team, Dec 2022, In: BMC infectious diseases. 22, 1, 466. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1186/s12879-022-07430-2
GSTM1 Copy Number and Kidney Disease in People With HIV
GEN-AFRICA study group, Aug 2022, In: Kidney International Reports. 7, 8, p. 1901-1904 4 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/j.ekir.2022.05.003
The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection—study protocol for a two-stage randomised phase II trial
Lee, M. J., Collins, S., Babalis, D., Johnson, N., Falaschetti, E., Prevost, A. T., Ashraf, A., Jacob, M., Cole, T., Hurley, L., Pace, M., Ogbe, A., Khan, M., Zacharopoulou, P., Brown, H., Sutherland, E., Box, H., Fox, J., Deeks, S., Horowitz, J., & 4 othersNussenzweig, M. C., Caskey, M., Frater, J. & Fidler, S., 5 Apr 2022, In: Trials. 23, 1, 26 p., 263. Research output: Contribution to journal › Review article › peer-review. DOIs: https://doi.org/10.1186/s13063-022-06151-w
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
Seow, J., Graham, C., Hallett, S., Lechmere, T., Maguire, T., Huettner, I., Cox, D., Khan, H., Pickering, S., Waters, A., Ward, C., Mant, C., Pitcher, M., Spencer, J., Fox, J., Malim, M. & Doores, K., 3 May 2022, In: Cell Reports. 39, 5, 110757. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/j.celrep.2022.110757
Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV
GEN-AFRICA study group & Post, F. A., 1 Apr 2022, In: Kidney International Reports. 7, 4, p. 786-796 11 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/j.ekir.2022.01.1054
Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study)
Lee, M. J., Snell, L. B., Douthwaite, S. T., Fidler, S., Fitzgerald, N., Goodwin, L., Hamzah, L., Kulasegaram, R., Lawrence, S., Lwanga, J., Marchant, R., Orkin, C., Palfreeman, A., Parthasarathi, P., Pareek, M., Ring, K., Sharaf, H., Shekarchi-Khanghahi, E., Simons, R., Teh, J. J., & 7 othersThornhill, J., van Halsema, C., Williamson, M., Wiselka, M., Nori, A., Fox, J. & Smith, C., Feb 2022, In: HIV MEDICINE. 23, 2, p. 121-133 13 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1111/hiv.13174
Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIV
GEN-AFRICA study group, Hung, R. K. Y., Binns-Roemer, E., Booth, J. W., Hilton, R., Fox, J., Burns, F., Harber, M., Ustianowski, A., Hamzah, L., Burns, J. E., Clarke, A., Price, D. A., Kegg, S., Onyango, D., Santana-Suarez, B., Campbell, L., Bramham, K., Sharpe, C. C., Sabin, C. A., & 31 othersWinkler, C. A., Post, F. A., Booth, J., Waters, A., Hand, J., Clarke, C., Murphy, S., Murphy, M., Campbell, M., Richardson, C., Knott, A., Weir, G., Cleig, R., Soviarova, H., Barbour, L., Adams, T., Kennard, V., Trevitt, V., Jones, R., Levy, J., Schoolmeester, A., Duro, S., Rabuya, M., Jordan, D., Solano, T., Post, F. A., Poulton, M., Flaherty, J., Patel, B., Manning, A. & Popoola, J., 1 Mar 2022, In: Kidney International Reports. 7, 3, p. 465-473 9 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/j.ekir.2021.12.007
Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort
Granger, L. A., Huettner, I., Debeljak, F., Kaleebu, P., Schechter, M., Tambussi, G., Weber, J., Miro, J. M., Phillips, R., Babiker, A., Cooper, D. A., Fisher, M., Ramjee, G., Fidler, S., Frater, J., Fox, J. & Doores, K. J., 1 Nov 2021, In: AIDS (London, England). 35, 13, p. 2073-2084 12 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1097/QAD.0000000000002988
The epidemiology of kidney disease in people of African ancestry with HIV in the UK
GEN-AFRICA study group, Aug 2021, In: EClinicalMedicine. 38, 101006. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/j.eclinm.2021.101006

View all publications

EDCTP

EU

Imperial College of Science Technology and Medicine, United Kingdom

London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom

University of Liverpool

Karolinska Institute, Sweden

Uganda Virus Research Institute (UVRI), Uganda

Desmond Tutu HIV Foundation

University of Zimbabwe College of Health Sciences – Clinical Trials Research Centre

University of Cape Town

Perinatal HIV Research Unit (PHRU), South Africa

Perinatal HIV Research Unit

WITS Health Consortium

EDCTP

European Union

Imperial College of Science, Technology and Medicine

London School of Hygiene & Tropical Medicine

University of Liverpool

Karolinska Institute

Desmond Tutu HIV Foundation

University of Cape Town

University of Zimbabwe College of Health Sciences Clinical Trials Research Centre

The Perinatal HIV Research Unit

Wits Health Consortium

Group lead

Julie-fox-160x160

Dr Julie Fox

Lead Investigator